Neurostimulation Devices Market To Reach $13.93 Billion By 2033

Neurostimulation Devices Market Growth & Trends

The global neurostimulation devices market size is expected to reach USD 13.93 billion by 2033, registering a CAGR of 10.29% from 2025 to 2033, according to a new report by Grand View Research, Inc. Increasing prevalence of chronic diseases, such as migraine and epilepsy, due to unhealthy diets & lifestyle, and rising geriatric population across the globe are expected to be the major growth-driving factors for the market. On the other hand, adverse effects and risks associated with neurostimulation devices and stringent regulations regarding product approval are expected to hamper the market growth to some extent. The increasing incidence of Road Traffic Accidents (RTAs) is another key factor supporting the market development.

In addition, manufacturers are investing in R&D activities to develop new products with advanced technology, such as MRI safety-incorporated devices by Medtronic Inc. and minimally invasive transdermal neuromodulation technology by Neurowave Medical Technologies. Asia Pacific is projected to be the fastest-growing regional market from 2023 to 2030 on account of the rising healthcare expenditures and rapid economic growth in emerging countries, such as India and China. The presence of unmet medical needs and untapped markets are also boosting the market growth in the region. Moreover, changing lifestyles and eating habits resulting in various lifestyle-related diseases will contribute to the regional market growth. The growing cases of RTAs and resultant nerve injuries, which require neurostimulation postoperatively, are also likely to boost the product demand.

 Request a free sample copy or view the report summary: Neurostimulation Devices Market Report

Neurostimulation Devices Market Report Highlights

• North America is estimated to dominate the global market over the forecast period due to the rising product demand as an add-on therapy and high disposable income & patient awareness levels

• The presence of sophisticated healthcare infrastructure and the growing prevalence of target diseases, such as epilepsy, Parkinson’s disease, and incontinence, are expected to drive the market growth further

• The spinal cord stimulation product segment led the market in 2024 as these devices were the prime neurostimulation products to be commercialized

• Pain management was the dominant application segment in 2024, in terms of revenue share, due to the high prevalence of chronic pain disorders and extensive product usage for pain management

• New product and technological developments are the key business strategies followed by most of the market players

Neurostimulation Devices Market Segmentation

Grand View Research has segmented the global neurostimulation devices market based on product, application, end use, and region:

Neurostimulation Devices Product Outlook (Revenue, USD Million, 2021 - 2033)

• Spinal Cord Stimulators

• Deep Brain Stimulators

• Sacral Nerve Stimulators

• Vagus Nerve Stimulators

• Gastric Electrical Stimulation

• Others

Neurostimulation Devices Application Outlook (Revenue, USD Million, 2021 - 2033)

• Parkinson’s Disease

• Chronic Pain

• Migraine

• Epilepsy

• Tremor

• Depression

• Urinary & Fecal Incontinence

• Others

Neurostimulation Devices End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Hospitals & Ambulatory Surgery Centers (ASC)

• Clinics & Physiotherapy Centers

• Others

Neurostimulation Devices Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players Neurostimulation Devices Market

• Abbott (St. Jude Medical)

• Medtronic

• Boston Scientific Corporation

• Aleva Neurotherapeutics

• Nexstim

• LivaNova PLC

• Neuropace Inc.

• Nevro Corporation

• Nalu Medical

• Mainstay Medical

• Saluda Medical Pty Ltd

• Biotronik

• electroCore, Inc.

• MicroTransponder Inc.

• tVNS Technologies GmbH

• Laborie

• Axonics, Inc.